Skip to main content

ERRATUM article

Front. Oncol., 05 September 2023
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1282057

Erratum: Extracellular volume fraction using contrast-enhanced CT is useful in differentiating intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma

This article is an erratum on:

  1. Extracellular volume fraction using contrast-enhanced CT is useful in differentiating intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Extracellular volume fraction using contrast-enhanced CT is useful in differentiating intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma.

by Honda T, Onishi H, Fukui H, Yano K, Kiso K, Nakamoto A, Tsuboyama T, Ota T, Tatsumi M, Tahara S, Kobayashi S, Eguchi H and Tomiyama N (2023) Front. Oncol. 13:1214977. doi: 10.3389/fonc.2023.1214977

Due to a production error, there was a mistake in Figure 4 as published. In the figure, subfigure (C) is incorrectly labeled as (D). The corrected Figure 4 appears below. The publisher apologizes for this mistake.

FIGURE 4
www.frontiersin.org

Figure 4 A 63-year-old man with a typical intrahepatic cholangiocarcinoma. Precontrast CT shows a hypodense lesion between the left and right lobes of the liver (A). The lesion shows rim enhancement during the arterial phase (B) and progressive enhancement during the equilibrium phase (C). Tumor extracellular volume fraction (fECV) is 52.6%, which exceeds the cutoff value (41.5%). Fibrosis is observed in the tumor histopathologically (D, ×4, hematoxylin-eosin stain).

The original version of this article has been updated.

Keywords: extracellular space, carcinoma, hepatocellular, cholangiocarcinoma, multidetector computed tomography, contrast media

Citation: Frontiers Production Office (2023) Erratum: Extracellular volume fraction using contrast-enhanced CT is useful in differentiating intrahepatic cholangiocellular carcinoma from hepatocellular carcinoma. Front. Oncol. 13:1282057. doi: 10.3389/fonc.2023.1282057

Received: 23 August 2023; Accepted: 23 August 2023;
Published: 05 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.